Alembic Pharma to launch 30 drugs
The Vadodra based drug firm will add more drugs to its domestic and international portfolio.
Ahmedabad, August 8, 2013: Alembic Pharmaceuticals plans to add 30 drugs in the domestic market and another 10 products in the US market during the current fiscal. The company reported a 51 per cent rise in its net profit for the first quarter that ended in June 2013. While the new drug launches in the US and regulated market would depend on the approval of ANDA and expiry of patent drugs, the company plans to add more drugs in the speciality segment in the domestic market.
It may be noted here that the company reported a 16 per cent rise in revenue to Rs 429 crore for the quarter ended June 30, 2013, compared to Rs 368 crore in the corresponding quarter last year.
The domestic branded formulation segment of the company grew by 15 per cent and the overall domestic business grew at a rate of 26 per cent.